Quantitative analysis for Alto Neuroscience, Inc. (ANRO) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Strong Buy (75.0) (grade A). 30 signals analyzed (24 differentiated alt-data).
ANRO stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-28 | $24.99 | $23.69 | $24.47 |
| 2026-05-08 | $24.91 | $23.65 | $24.26 |
| 2026-05-20 | $20.96 | $20.09 | $20.78 |
| 2026-06-02 | $19.88 | $18.47 | $18.71 |
| 2026-06-12 | $22.79 | $21.24 | $21.47 |
| 2026-06-25 | $26.38 | $24.82 | $25.30 |
| 2026-07-08 | $27.20 | $24.58 | $26.09 |
| 2026-07-20 | $28.62 | $25.66 | $25.93 |
| 2026-07-30 | $28.75 | $26.51 | $28.63 |
| 2026-08-12 | $29.70 | $28.24 | $29.18 |
| 2026-08-24 | $36.99 | $33.52 | $36.25 |
| 2026-09-03 | $37.36 | $35.91 | $36.40 |
How Alto Neuroscience, Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| CLYM | Climb Bio, Inc. | $717M | 43.0 |
| BBOT | BridgeBio Oncology Therapeutics Inc. | $706M | — |
| TLRY | Tilray Brands, Inc. | $647M | — |
| SPTX | Seaport Therapeutics, Inc. Common Stock | $837M | — |
View all Health Care stocks by valuation and signals →
Alto Neuroscience, Inc. (ANRO) scores Strong Buy (75.0), and the composite conceals a 98-point disagreement between its dimensions. It is strongest on ML forecast at 99 and analyst consensus at 95, and weakest on competitive moat at 1. A stock can carry ML forecast that high while competitive moat sits at 1; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| ML forecast | 99 |
| analyst consensus | 95 |
| technicals | 75 |
| competitive moat | 1 |
StoQuant analyzes 30 signals (24 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Alto Neuroscience, Inc. (ANRO): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/ANRO"><img src="https://stoquant.com/badge/ANRO.svg" alt="Alto Neuroscience, Inc. (ANRO) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.